Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06188559 · ClinicalTrials.gov registry record · Phase 2

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by Eisai.

Active
Registry status
Phase 2
Development phase
135
Enrollment target
20
Study locations

NCT06188559 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by Eisai. The registered enrollment target is 135 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06188559, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by Eisai.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
135 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of the Dose Optimization (Part 1) of this study is to assess the safety and tolerability of BB-1701 and to determine the recommended dose (RD) of BB-1701 for Dose Expansion (Part 2). The primary purpose of Dose Expansion (Part 2) is to assess the antitumor activity of BB-1701 at RD in the selected population(s) of breast cancer (BC).

Conditions Studied

Breast Cancer

Interventions

  • DRUG BB-1701

Study Locations (20)

California

  • Cancer and Blood Specialty Clinic - Los Alamitos
  • UCLA Center for East-West Medicine - Los Angeles
  • UCSF - San Francisco

New Jersey

  • Astera Cancer Care - East Brunswick
  • Summit Medical Group - Florham Park
  • Rutgers Cancer Institute of New Jersey - New Brunswick

Florida

  • AdventHealth Cancer Institute - Orlando - Orlando
  • Moffitt Cancer Center - Tampa

Indiana

  • Fort Wayne Medical Oncology & Hematology - Fort Wayne
  • Community Cancer Center South - Indianapolis

Nebraska

  • NHO Revive Research Institute LLC - Lincoln
  • Nebraska Cancer Specialist - Omaha

Ohio

  • Cleveland Clinic - Fairview Hospital - Cancer Center (Moll Cancer Center) - Cleveland
  • Cleveland Clinic - Hillcrest Hospital - Hillcrest Cancer Center - Cleveland

Connecticut

  • Yale New Haven Hospital - New Haven

Iowa

  • Mission Blood and Cancer - Des Moines

Trial Details

FieldValue
Enrollment Target 135 participants
Start Date 2024-04-10
Est. Completion 2027-03-31
Phase Phase 2

Sponsor

Eisai

287 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06188559

The ClinicalTrials.gov registry entry for NCT06188559 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which BB-1701 is the first listed.

NCT06188559 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New Jersey, Florida.

Frequently Asked Questions

What is clinical trial NCT06188559 about?

NCT06188559 is a clinical study titled "A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer". The primary purpose of the Dose Optimization (Part 1) of this study is to assess the safety and tolerability of BB-1701 and to determine the recommended dose (RD) of BB-1701 for Dose Expansion (Part 2). The primary purpose of Dose Expansion (Part 2) is to assess the antitumor activity of BB-1701 at ...

What is the current status of trial NCT06188559?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2024-04-10. Estimated completion is 2027-03-31.

What conditions does trial NCT06188559 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT06188559?

The interventions under investigation include: BB-1701 (DRUG).

Who is sponsoring clinical trial NCT06188559?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06188559 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.